ArticleVirology journal2023
Development and validation of a duplex real-time PCR for the rapid detection and quantitation of HTLV-1.
Article in Virology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease.Journal of neurovirology · 2026Review
- Diagnostic utility and pitfalls of human T-lymphotropic virus serology in adult T-cell leukemia/lymphoma: evidence from a 25-year pathology-based nonendemic cohort.The journal of pathology. Clinical research · 2026Article
- Extending the Potential of Digital Droplet PCR by Expressing Amplified Genes and Assaying Their Phenotype.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Can Oncogenic Animal Viruses Pose a Threat to Humans?Pathogens (Basel, Switzerland) · 2025Review
- A Simple, Highly Sensitive, and Highly Specific Dot-Blot-Based Immunoassay for Serodiagnosis of HTLV-1 in Resource-Limited Settings.Tropical medicine and infectious disease · 2025Article
- Limitations of human t-lymphotropic virus type 1 antibody testing in hospitals of endemic regions in China.Frontiers in cellular and infection microbiology · 2025Article
- BLV-CoCoMo Dual qPCR Assay Targeting LTR Region for Quantifying Bovine Leukemia Virus: Comparison with Multiplex Real-Time qPCR Assay TargetingPathogens (Basel, Switzerland) · 2024Article
- Article
- Genetic typing and intrafamilial transmission of human T-lymphotropic virus type 1 in non-endemic areas of China.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe HTLV-1 prevalence in China varies geographically, while HTLV-2 infection has rarely been found so far. Proviral load is one of the determining factors of pathogenesis and progression of HTLV-1 related diseases. However, neither molecular assays nor commercial kits are available for HTLV-1 diagnosis in China. The objective of the present study was to develop and validate a TaqMan qPCR assay for HTLV-1 proviral load quantification.
resultsA plasmid containing both the HTLV-1 of interest and a fragment of the RNase P (RPPH1) gene was constructed and used to establish the standard curves. The assay has a wide dynamic range (2.5 × 10
conclusionThe duplex qPCR developed here with high sensitivity, good specificity and reproducibility could accurately and quantitatively detect the HTLV-1 PVLs, which can be used to confirm the initial reactive samples for an improved cost/benefit ratio as well as to monitor the clinical progression and efficacy of therapy in patients with HTLV-1 related disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.